Consensus Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.6917 ^USD	-3.25%		-2.96%	+34.89%

Apr. 01	Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	MT
Mar. 29	Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	CI

Evolution of the average Target Price on Atara Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

59224039e38c726be89a712a5fbff4.XZDzwmp8my8oxTw4HnPScfgAwSss3XaODkfhntP_XPU.J928sCgb-n9gj3tJcgKkP45ahWdLkzi6a3OU2uOVJYc045eRIwT0GBukUw~c49b43356425852dd86749f46107c4bb

Analyst Recommendations on Atara Biotherapeutics, Inc.

Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	Apr. 01	MT
Goldman Sachs Cuts Price Target on Atara Biotherapeutics to $0.50 From $3, Maintains Sell Rating	Nov. 10	MT
Evercore ISI Downgrades Atara Biotherapeutics to In Line From Outperform	Nov. 09	MT
HC Wainwright Downgrades Atara Biotherapeutics to Neutral From Buy	Nov. 09	MT
Mizuho Securities Downgrades Atara Biotherapeutics to Neutral From Buy, Slashes Price Target to $1 From $31	Nov. 09	MT
Citigroup Adjusts Atara Biotherapeutics Price Target to $1.40 From $2, Maintains Sell Rating	23-08-21	MT
HC Wainwright Adjusts Atara Biotherapeutics Price Target to $28 From $27, Maintains Buy Rating	23-06-14	MT
Canaccord Genuity Adjusts Price Target on Atara Biotherapeutics to $20 From $50, Maintains Buy Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on Atara Biotherapeutics to $27 From $29, Maintains Buy Rating	23-02-09	MT
Mizuho Securities Reiterates Atara Biotherapeutics at Buy With $31 Price Target	23-02-07	MT
EF Hutton Initiates Atara Biotherapeutics at Buy With $25 Price Target	23-01-05	MT
Mizuho Securities Cuts Price Target on Atara Biotherapeutics to $31 From $39, Keeps Buy Rating	22-08-16	MT
Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $3 From $4, Keeps Sell Rating	22-08-09	MT
Citigroup Downgrades Atara Biotherapeutics to Sell From Neutral; Price Target is $3	22-07-20	MT
Stifel Cuts Atara Biotherapeutics to Hold From Buy, Price Target to $5 From $16	22-07-13	MT
JPMorgan Downgrades Atara Biotherapeutics to Neutral From Overweight; Price Target is $10	22-07-13	MT
Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $4 from $5, Keeps Sell Rating	22-05-24	MT
HC Wainwright Adjusts Atara Biotherapeutics' Price Target to $29 from $31, Keeps Buy Rating	22-05-23	MT
Citigroup Downgrades Atara Biotherapeutics to Neutral From Buy, Sets $8 Price Target	22-05-09	MT
Stifel Adjusts Price Target for Atara Biotherapeutics to $18 From $20, Maintains Buy Rating	22-05-06	MT
JPMorgan Adjusts Price Target on Atara Biotherapeutics to $22 From $27, Reiterates Overweight Rating	22-03-28	MT
Mizuho Securities Adjusts Atara Biotherapeutics' Price Target to $39 From $41, Reiterates Buy Rating	22-03-08	MT
JPMorgan Adjusts Price Target on Atara Biotherapeutics to $27 From $26, Maintains Overweight Rating	22-01-03	MT
ATARA BIOTHERAPEUTICS : JPMorgan Upgrades Atara Biotherapeutics to Overweight From Neutral, Adjusts Price Target to $29 From $23	21-05-13	MT
ATARA BIOTHERAPEUTICS : Citigroup Upgrades Atara Biotherapeutics to Buy From Neutral; Price Target is $27	21-03-02	MT